Glooko spent the week underscoring its strategy to build an integrated diabetes data ecosystem spanning inpatient and outpatient care. The company highlighted its participation in the 38th Annual Diabetes Conference in North Carolina, where it showcased connected-care solutions aimed at improving outcomes and streamlining clinician workflows.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Glooko also promoted its EndoTool inpatient glycemic management platform, citing data from Advocate Health’s 19-hospital network showing a 98% reduction in severe hypoglycemia versus paper protocols. This evidence was presented at the 2026 American Association of Clinical Endocrinology Annual Meeting, reinforcing the platform’s safety and scalability focus.
The company emphasized alignment with the American Diabetes Association’s 2026 Standards of Care, positioning EndoTool and its outpatient diabetes data platforms as an “actionable ecosystem” connecting hospital and ambulatory data. This standards-driven interoperability strategy targets large health systems and is designed to support enterprise-scale adoption and recurring software revenues.
On the outpatient side, Glooko spotlighted its EHR-integrated diabetes management tools via an on-demand webinar with Rady Children’s Hospital–San Diego and Michigan Medicine. By automating data flow into electronic health records and eliminating manual tasks such as printing and scanning, Glooko aims to enhance provider efficiency and data quality across clinics.
The company also drew attention to the Glooko Mobile App on Google Play, which consolidates data from more than 200 diabetes and health monitoring devices and apps. This interoperability is intended to give care teams a more comprehensive view of patient health and support data-driven treatment decisions, strengthening user stickiness and platform value.
Across communications, Glooko’s messaging centered on interoperability, workflow automation, and health-system scale rather than new contract or financial disclosures. The week’s developments collectively support a strategy of embedding the company’s technology deeply into clinical workflows, which could bolster its competitive positioning in digital diabetes management over time.